TORONTO, July 27, 2022 /CNW Telbec/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for people living with depression and related mental health disorders, is pleased to announce the addition of Jason Wolkove, Chief Information Officer and Daniel Herrera…


Previous articleU.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Next articleIncannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement